Prescription Status and Efficacy of OROS-MPH and Parent Perception in Children with Attention Deficit Hyperactivity Disorder : Multi-Center, Observational Study during 4 Weeks / 대한정신약물학회지

ABSTRACT

OBJECTIVE: This study was performed to evaluate the current prescription status by clinicians, the efficacy of once-daily OROS-methylphenidate (MPH) in the treatment of children with attention deficit hyperactivity disorder (ADHD) and parent anticipation, concern and satisfaction about treatment. METHODS: The subjects with ADHD between 6 and 18 years were prescribed 18, 36, 54 mg OROS-MPH, depending on clinician's judgment. ADHD symptoms and improvement were assessed by clinicians using the Clinical Global Impression-Severity (CGI-S) and the Clinical Global Impression-Improvement (CGI-I). Parents were also measured the Conners Abbreviated Parent Rating Scale (CAPRS) and by the questionnaires inquiring about parental anticipation, concern, satisfaction about treatment at baseline and the 4th week after OROS-MPH trial. RESULTS: A total of 704 subjects were enrolled in the observational study and 645 completed the trial. There was an 18% increase in mean daily dose and 14% increase in mean daily dose per kg during 4 weeks. About 56% of subjects were scored 2 or less by the CGI-I. CAPRS scores were significantly decreased from 14.8 to 8.81. Before treatment, parents anticipated the symptom improvement firstly, followed by education material, parental education and non-pharmacological treatment. Parent concerned about side effect, growth, dependency and abuse. In general, 95% of parent were satisfied with OROS-MPH . CONCLUSION: According to this study, there was an increase in mean daily dose over the study period. OROS-MPH appears to be efficacious for decreasing the symptoms of ADHD and was satisfactory to parents of children with ADHD.